Biomedicine

Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis

Published in Immunotherapy Weekly, October 24th, 2007

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, is presenting new data this week showing that its drug candidate HE3286, a novel orally bio-available anti-inflammatory which has previously demonstrated benefit in animal models of rheumatoid arthritis, also provided benefit in an animal model of ulcerative colitis.

The data were presented at the 3rd International Conference on Autoimmunity: Mechanisms and Novel Treatments, in Rhodes, Greece, by Ferdinando Nicoletti, MD, professor of biomedical sciences at the University of Catania School of Medicine,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2007-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry